2018 Speakers

  • Chris Allen

    Managing Director Broughton Laboratories

    With over 20 years’ industry experience in the analytical science industry, Chris Allen is the co-founder of Broughton Laboratories and serves as the Managing Director. Chris joined Broughton in 2006 coming from a contract analytical laboratory within the animal health industry. His educational background is a BSc in Chemistry from The University of Hull.

    Originally, Chris began his career as an Analytical Chemist within a global medical technology business specialising in medical devices and wound care products. From there, he has held positions where he gained thorough knowledge of analytical techniques and operational management. Since his appointment as MD in 2011, Chris’ focus is to provide collaborative leadership as well as develop and implement strategic plans that deliver value and unrivalled experiences to customers. Chris’ first involvement in the analysis of electronic cigarettes began in 2009 supporting the development and regulatory programme for e-Voke, the first electronic cigarette to be granted a medicinal license. Since then, Chris and the team at Broughton have worked on numerous projects in support of EU TPD, EU Medicinal Product and PMTA applications”

  • Eduardo Berea

    Member of the Board CORESTA

    Eduardo Berea has a degree in Agricultural Engineering from the Universidad Autonoma Metropolitana-Xochimilco, Mexico.

    He spent 5 years working in R&D on natural colorants and 10 years of R&D in Beverage and Dairy Industry.

    Since 1999, he has been working in the Flavour Industry with main responsibilities in Sales, Marketing and Technical Support in International Markets.

    Eduardo joined Mother Murphy’s Laboratories (MML) in 2006 where he is currently the International Sales Manager and Tobacco Division Director. He also serves as the International Sales Manager of Alternative Ingredients, a subsidiary company of MML fully dedicated to the ENDS industry. Alternative Ingredients is a Member of the Board of CORESTA.

  • Gal Cohen

    Senior Director, Scientific Affairs JUUL Labs

    Dr. Gal Cohen is Head of Scientific Affairs at JUUL Labs.  Dr. Cohen earned a Ph.D. in Neuroscience from Stanford University. He has 30 years' experience spanning academia, pharmaceutical and medical device companies, including Medtronic and Nektar Therapeutics (pulmonary medicines division acquired by Novartis.)

  • John Dunne

    Managing Director E-Liquid Brands

    John Dunne is currently the Managing Director of E-liquid Brands based in London . E-Liquid Brands is a manufacturer and distributor of premium UK and US e-liquids who’s brands include Ohmbrew, DripWich, Squeezee , Snodrone and Wanderlust.

    John has a strong background and reputation in the European Electronic cigarette industry having held senior executive positions in some of Europe’s biggest companies, and advises many leading industry analysists, financial institutions and media organizations looking at the vaping category.

  • Ian Fearon

    Senior Director Clinical and Regulatory Affairs EMEA JUUL

    Ian is a Director of Tobacco Research at Celerion, a provider of clinical research capabilities and expertise to the tobacco and e-cigarette industry. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation.  Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada.  Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters which have generated over 2,200 citations.

  • Scott Fletcher

    Director of Analytical Services Hall Analytical

    Scott is the Director of Analytical Services at Crawford Scientific where he heads up their specialist MS based laboratory, Hall Analytical, in Manchester, UK.

    Hall Analytical has a long association with e-cigarette analysis and development with over 10 years experience of preforming analytical testing on the very early cigalike prototypes.

    Before this he spent many years working as a professional trainer and consultant in analytical chemistry and prior to that he worked in the pharmaceutical industry in the incredibly analogous field of developing dry powder inhalers!

    Scott sits on the Separation Science Committee of the Royal Society of Chemistry, of whom he is a Fellow, and on the Editorial Advisory Board of various Separation Science publications and is regular speaker at national and internal conferences. 

  • Judy E. Gibson

    Secretary General (CEO) INNCO (International Network of Nicotine Consumer Organisations)

    Judy Gibson is CEO of The International Network of Nicotine Consumer Organisations (INNCO).

    Her diverse career includes WRAF SNCO, CID Officer, Sales Manager for International Print/Packaging Company.  Company Director in artiste management and PR/Film Manager in regional theatre. More recently she has worked as a freelance Community Flood Consultant undertaking nationwide projects for the UK Environment Agency.

    Having suffered various iterations of e-cigarettes since 2010, she became an ex-smoker in 2015 following the birth of decent sub-ohm tanks. She is also quite oldish & is fond of politics, reading, Sibelius and red wine ;-)

    INNCO is a Civil Society organisation currently representing 31 consumer advocate organisations in 27 countries in five continents. It’s mission is to reduce the harm posed by combustible and toxic oral forms of tobacco by monitoring, supporting and promoting the rights and needs of the population to reduce their health risk by choosing significantly safer forms of nicotine use.

  • Olivia Hibbert

    Scientific Regulatory Engagement Manager Imperial Brands PLC

    Olivia works in Scientific Regulatory Engagement at Imperial Brands, based in Bristol in the UK. Her interests include regulatory developments in e-vapour products, nicotine, and other next generation products.

    Olivia is a member of the British Standard Institute’s committee on e-cigarettes, working both at the European committee on e-cigarettes (CEN TC 437) and the international standards body’s technical committee on vaping products (ISO TC 126 SC3). She previously worked as a project manager within Imperial’s Innovative Engineering team, prior to which she worked in drug discovery for a pharmaceutical company. She holds a BSc and an MSci in chemistry from the University of Bristol.

  • Liam Humberstone

    Technical Director at Totally Wicked Product Design & Engineering at Independent British Vape Trade Association (IBVTA)

    Liam Humberstone is Technical Director at Totally Wicked Limited.  His involvement with standards and regulations for e-cigarettes and e-liquid started with a notorious legal challenge, but he has since worked collaboratively with regulators at UK National, European and other International levels.  His background is in design engineering and scientific research, and he has been involved in the e-cigarette industry since 2011.

  • Ian Jones

    Vice President Reduced-Risk Products Japan Tobacco International

    Ian Jones is the Reduced-Risk Products Vice President at Japan Tobacco International (JTI), based in Geneva, Switzerland.

    He joined JTI in 2006 from the University of Bath, UK, where he was a lecturer in Developmental Neuroscience at the Department of Biology and Biochemistry. Prior to this he held post-doctoral research positions at the Universities of Bath, Oxford and London, specializing in the anatomical neuropharmacology of nicotinic acetylcholine receptors. He holds a PhD in cell physiology, completed at Imperial College, London (1995).

  • Beryl Keeley

    Advertising Standards and Outreach Unit Manager Medicines and Healthcare products Regulatory Agency (MHRA)

    Beryl Keeley has a background in biochemistry and has worked in various areas in Government and previously in the pharmaceutical industry.  Beryl is currently Advertising Standards and Outreach Unit Manager at the Medicines and Healthcare products Regulatory Agency.  The Unit has responsibility for the regulation of medicines advertising in the UK and for production of Drug Safety Update and sits within the MHRA Vigilance and Risk Management of Medicines Division.  Beryl has recently completed a project to lead the UK implement of the Tobacco Products Directive notification scheme for e-cigarettes.  

  • Patricia I. Kovacevic

    General Counselor and Chief Compliance Officer Consultant Independent Consultant

    A global legal and compliance industry expert Patricia I. Kovacevic’s experience comprises general counsel and chief compliance officer roles at Nicopure Labs LLC, and leading senior legal and compliance positions at, among others, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy, product development and launch. Kovacevic served on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. In the past she was a United Nations staff member, served on the U.N.’s Public-Private Partnership Commission and was also an adviser to the Council for Burley Tobacco. Kovacevic is admitted to practice in New York and before the Supreme Court of the United States. She holds a J.D. from Columbia Law School in New York and has completed the Harvard Business School “Corporate Leader” course. She is fluent in seven European languages. 

  • Ramunas Macius

    Vice-President, Corporate Development, Reduced-Risk Products Japan Tobacco International

    Ramunas Macius, a Lithuanian national, joined Japan Tobacco International in May 2007 as a Head of Corporate Affairs for the Baltic markets based in Vilnius. In 2011 his responsibility has been expanded to Denmark, Norway, Iceland and Finland. Ramunas coordinated JTI engagement with local governments on regulatory and excise tax issues. He also managed media and community investment projects.

    In 2015 Ramunas Macius was promoted to the position of Vice-President, Corporate Affairs and Communications, Central Europe Region covering 25 markets. His responsibility included strategic response to the regulatory challenges within the Region.

    Ramunas Macius was appointed to the current role of VP Corporate Development, Reduced-Risk Products (RRP), in December 2017. His primary objective is to represent JTI view and contribute to the public debate on complex and emerging regulatory regimes of the RRPs.

    Previous experience

    Ramunas Macius began his career in politics as a member of media relations team of Lithuanian President Valdas Adamkus (1998-2003). He also worked in the Ministry of Foreign Affairs (2004-2006) and Embassy of Lithuania in Brussels (2006-2007).

    Ramunas Macius holds a Master’s degree of International Relations and Political Science from Vilnius University and a Master's in Business Administration from Baltic Management Institute.

  • Neil McCallum

    CEO JAC Vapour

    Neil started his career by obtaining an engineering degree, followed by a Master’s in facilities management before joining Morgan Stanley at the age of 26. He eventually moved out of banking to join the Scottish Environment Protection Agency (Sepa) as Head of Facilities and Estates. His last post before joining JAC Vapour Ltd in October 2016 as CEO was as Managing Director of Critiqom Ltd where sales were lifted by 60% and profit by 50% during his time with the Company.

  • Willie McKinney

    Vice President Regulatory Sciences Altria Client Services

    Willie J. McKinney, Ph.D., D.A.B.T., serves as Vice President, Regulatory Sciences, for Altria Client Services (ALCS) in Richmond, Virginia. In this role, he leads a team that develops scientific evaluation and regulatory science strategies for Altria's family of companies.

    Dr. McKinney has held a variety of positions with increasing responsibilities within the Altria family of companies. He served as Senior Director, Product Integrity and Regulatory Reporting, where he led a team that develops scientific evaluation and regulatory submission strategies for Altria's family of companies; Director, Strategic Product Planning, where he provided operational and strategic support; Senior Manager, Cellular & Molecular Biology Group; and as a visiting scientist at the Institute for Biologische Forschung GmbH (INBIFO) in Köln, Germany.

    Before joining the Altria family of companies in 1998, Dr. McKinney held a variety of academic and research roles, including working as an Associate Research Scientist, Nelson Institute of Environmental Medicine, NYU Medical Center, Tuxedo, N.Y., and as a Graduate Research Assistant at the Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill. He also held Toxicology Intern and Research Assistant roles with several government agencies. Dr. McKinney is board certified in Toxicology by the American Board of Toxicology. He has published numerous professional articles related to his research and work, and has presented before various scientific organizations. He holds a BS degree in Biology from Xavier University, an MS in Biology from North Carolina Central University, and a PhD in Environmental Toxicology from the University of North Carolina at Chapel Hill. He serves on the Higher Achievement Board and on the Richmond Higher Achievement Advisory Board.

  • David McLaughlin

    Director, Business Development Elucid8

    David is director of business development at Elucid8, a speciality consultancy company that brings together experts with over 90 years of industry experience in nicotine products and offers tailored assistance in product development, consumer research, patent/literature reviews and regulatory compliance.

    Prior to establishing Elucid8, David was Director of R&D for ‘Next Generation Products’  within a major FMCG company where he has a proven track record of developing high performing teams and bringing business-relevant inhalable products to market within a multicultural environment.

    David holds a BSc in Chemistry from University of St.Andrews; a PhD in drug delivery from Queens University of Belfast; a MBA from Ulster University and has published several patents in fields of novel products and technology.

  • Matthew Moden

    Managing Director Liberty Flights

    Matthew Moden is the Honorary Secretary of the IBVTA and Chairman of the IBVTA Manufacturers and Importers Committee.  Matthew is the Managing Director of Liberty Flights, co-founding the business in 2009.  Matthew’s career began in broadcasting with the BBC and evolved towards new media and commercial digital spheres. Matthew’s approach to the vaping sector has led him to develop successful business models in manufacture, convenience retail and wholesale.  

  • James Murphy

    Head of Biosciences British American Tobacco

    Dr James Murphy is the head of reduced risk substantiation at British American Tobacco (BAT). He oversees all of BAT’s preclinical and clinical research programs and is working on research methodologies to substantiate the reduced risk potential of next-generation products.

    James joined BAT in 2005 following a postdoctoral research position at the Nara Institute of Science & Technology in Japan, where he was developing novel polymeric-based drug delivery systems.  He has held a variety of roles leading the development and assessment of novel technologies and, most recently, the development and commercialisation of Vype e-cigarettes. In his current role James oversees all of our pre-clinical and clinical research programs and his team are working on research methodologies to substantiate the reduced-risk potential of next-generation products.

  • Sudhanshu Patwardhan

    Senior International Engagement Manager British American Tobacco / Nicoventures

    Dr Sudhanshu Patwardhan is a medical doctor and an MBA with nearly two decades of international experience in biomedical research and regulatory strategy in the pharmaceutical and tobacco industries. He has worked in the British American Tobacco Group for the thirteen years, focusing on tobacco harm reduction science, policy and regulation. He strongly believes that globally accepted quality and safety standards for vapour products are key to assuring regulators and also inspiring consumer confidence to switch out of smoking. Following his work in the BSI steering group to create the world’s first quality and safety specifications for vapour products, he is now a Co-convenor at the European CEN working group on definitions and terminology related to vapour products.

  • Tim Phillips

    Managing Director ECigIntelligence

    The founder and managing director of ECigIntelligence, Tim is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded start-up in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practice from the University of Law, London and a Masters in Geology from Oxford University.

  • Umberto Roccatti

    President PUFF STORE Group

    With nearly 10 years of experince in the ENDS market, Umberto Roccatti is the founder and President of PUFF Group, a series of companies operating in the production, distribution and retailing  of electronic cigarette

    Gruaduated in Marketing at Turin Business University in 2000, he spent his first 12 years of career as export manager and business developer in food and Beverage industry, mainly in spirits and processed meat, working around 4 continents.

    In 2009 Umberto founded PUFF GROUP. The company grew fastly in terms of retailing reaching 250 ecig stores in Italy, the Netherlands and Spain. In 2013 PUFF Group opened it’s own eliquid production plant  and an R&D center in China, developing consistent, safe and cool products  internationally distributed.

    In 2018 Umberto became President of ANAFE, Italian Vaping Producer Association, that co-founded in 2013.

    His 360°  and vertical know how, its networking and its commitment into electonic cigarette market, make Umberto a reference in the Europwide industry.

  • Dr. Lorraine Rusch

    President High Point Clinical Trials Center

    Dr. Rusch is a highly experienced drug development scientist and executive, specializing in early clinical research and development services. She has significant drug development expertise from the biotechnology industry and is a leader in the contract research organization sector, known for expanding research capabilities and creating unique service offerings to the biopharma industry.

  • Dr Andrea Vansickel

    Manager Consumer & Marketplace Insights Altria Client Services

    Andrea Rae Vansickel, Ph.D. is a classically trained behavioral pharmacologist, educated in experimental psychology-behavioral neuroscience, and psychopharmacology at the University of Kentucky and in the clinical pharmacology of tobacco at Virginia Commonwealth University.   Dr. Vansickel has published over 20 papers and book chapters related to human models of drug self-administration, human drug discrimination, human abuse liability testing, and the clinical pharmacology of e-vapor products, among others.  Dr. Vansickel has been building programs and infrastructure to support regulatory research and engagement efforts for Altria since January of 2012. These programs relate to tobacco abuse liability testing, e-vapor topography, cross-sectional surveys, actual use trials and, most recently, prospective cohort studies. 

  • Tanvir Walele

    Director - Scientific Affairs Fontem Ventures

    Tan is a European Registered Toxicologist with significant experience in risk assessment and risk management, in-vitro toxicity models and clinical research. At Fontem Ventures he is responsible for a team of scientists supporting non-tobacco, next generation products and heads up their stewardship function which includes liaising with external advisors, engagement and regulatory authorities and providing advice on and management of product testing strategies. In addition Tan is responsible for the compilation and provision of robust & substantive scientific information in support of products as required by regulations worldwide, to ensure their approval by government authorities. This includes the provision of dossiers through regulatory frameworks such as EUTPD, Medicinal Licensing and US FDA.

    Tan's qualifications include: European Registered Toxicologist, ERT; Toxicology, MSc; Medical Biochemistry, BSc

  • Shaun Wedgewood

    Technical Director EL-Science

    Shaun is an analytical chemist with over 20 years’ experience working within some of the world’s top chemical companies.

    Shaun began his career developing flavour and fragrance concentrates and additives for a company now known as Fruitarom. He then worked across a range of chemical companies before settling down with InterTek and British Petroleum (BP) for a five year period.

    Seeking a new challenge and noting legislative changes in the way the UK handles its hazardous waste, Shaun entered discussions with an innovative newly formed company called Augean in 2007. Shaun was employed at a senior management level to create and implement the UK’s first dedicated, accredited hazardous waste laboratory. As well as offering in-depth analytical facilities with some of the most advanced analytical instrumentation commercially available, the laboratory team also developed Augean’s sustainable process technology allowing Augean to safely manage some of the UK’s most difficult hazardous waste streams, including low level radioactive material.

    Shaun then turned his attention to electronic cigarettes, incorporating i-Vapo Limited with his business partner, Andrew, in May 2013.

  • Mary Yates

    Nurse Consultant - Health Promotion and Wellbeing South London and Maudsley NHS Foundation Trust

    Mary Yates is a Nurse Consultant (Health Promotion & Wellbeing) working in South London & Maudsley NHS Foundation Trust (SLaM).  She is a registered Learning Disability and Mental Health Nurse.  Her thirty years of clinical experience has been predominantly in acute adult, forensic and learning-disability mental health care settings.

    It was whilst working in forensic services that she developed a special interest in patient’s physical health care needs.  Her ambition is to reduce preventable disease and premature mortality in people with mental health problems.  She believes that recovery from mental health problems is not possible for smokers unless tobacco dependence is addressed.  She argues for parity of esteem and initiatives to reduce variation and tackle inequality.

    Mary has provided leadership for the introduction of a smoke-free policy in SLaM since March 2013.  She contributed to the development of NICE Guidance on Smoking: acute, maternity and mental health services, in November 2013.  She is currently an active member of the Smoking & Mental Health Partnership and a member of the Leading Change Adding Value through smoking cessation initiative.  

  • Richard Young

    Principal Toxicologist and Managing Director bibra toxicology advice and consulting

    Richard is a RSB/BTS and European Registered Toxicologist (ERT) and has been working as a desk-based toxicologist at bibra for 15 years. His special interests include the pragmatic application of risk assessment methodology to mammalian toxicity data sets, in order to derive robust conclusions on toxicological acceptability of exposures and on health risks to exposed populations. In recent years he has been helping companies assess the potential human health effects of Non-Tobacco Nicotine Delivery Devices (NTNDDs). This has included assisting in the production of toxicity monographs on over 300 e-liquid ingredients, assisting with the EU CLP classification of e-liquids, and proposing toxicologically tolerable levels for key e-liquid ingredients and e-cig emissions (e.g. several aldehydes).